Informing women with breast cancer about endocrine therapy: Effects on knowledge and adherence

Psycho-Oncology

Volumn 24, Issue 2, 2015, Pages 130-137

  Heisig, Sarah R ^a   Shedden Mora, Meike C ^b   Von Blanckenburg, Pia ^c   Schuricht, Franziska ^c   Rief, Winfried ^c   Albert, Ute Susann ^c   Nestoriuc, Yvonne ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Adherence in oncology; Adjuvant endocrine therapy; Breast cancer; Disease knowledge; Treatment information

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ASSESSMENT; COGNITION; COHORT ANALYSIS; COMPREHENSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INFORMATION; DRUG SAFETY; EDUCATIONAL STATUS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FOLLOW UP; HUMAN; KNOWLEDGE; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICAL INFORMATION; MEDICATION COMPLIANCE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PARTIAL MASTECTOMY; PATIENT COMPLIANCE; PATIENT SATISFACTION; PLEURA EFFUSION; TREATMENT DURATION; ADJUVANT CHEMOTHERAPY; AGE; ATTITUDE TO HEALTH; BREAST NEOPLASMS; METABOLISM; PATIENT EDUCATION; PROCEDURES; SEGMENTAL MASTECTOMY;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COGNITION; COHORT STUDIES; EDUCATIONAL STATUS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MASTECTOMY; MASTECTOMY, SEGMENTAL; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; PATIENT SATISFACTION; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 84921409366     PISSN: 10579249     EISSN: 10991611     Source Type: Journal    
DOI: 10.1002/pon.3611     Document Type: Article

References (38)

1. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2012;381:805-816. DOI: 10.1016/S0140-6736(12)61963-1
2. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717. DOI: 10.1016/S0140-6736(05)66544-0
3. Regan MM, Neven P, Giobbie-Hurder A, et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol 2011;12:1101-1108. DOI: 10.1016/S1470-2045(11)70270-4
4. Cella D, Fallowfield LJ, Barker P, Cuzick J, Locker G, Howell A. Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat 2006;100:273-284. DOI: 10.1007/s10549-006-9260-6
5. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-62. DOI: 10.1016/S0140-6736(04)17666-6
6. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003;21:602-606. DOI: 10.1200/JCO.2003.07.071
7. Ziller V, Kalder M, Albert U-S, et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 2009;20:431-436. DOI: 10.1093/annonc/mdn646
8. Chlebowski RT, Geller ML. Adherence to endocrine therapy for breast cancer. Oncology 2006;71:1-9. DOI: 10.1159/000100444
9. Gold DT, McClung B. Approaches to patient education: emphasizing the long-term value of compliance and persistence. Am J Med 2006;119:S32-S37. DOI: 10.1016/j.amjmed.2005.12.021
10. Horne R, Hankins M, Jenkins R. The Satisfaction with Information about Medicines Scale (SIMS): a new measurement tool for audit and research. Qual Health Care 2001;10:135-140. DOI: 10.1136/qhc.0100135
11. Francis V, Korsch B, Morris M. Gaps in doctor-patient communication: patients' response to medical advice. N Engl J Med 1969;280:535-540. DOI: 10.1056/NEJM196903062801004
12. Arnold-Wörner N, Holle R, Rathmann W, Mielck A. The importance of specialist treatment, treatment satisfaction and diabetes education for the compliance of subjects with type 2 diabetes - results from a population-based survey. Exp Clin Endocrinol Diabetes: Off J, Ger Soc Endocrinol Ger Diabetes Assoc 2008;116:123-128. DOI: 10.1055/s-2007-990297
13. Hadji P. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 2010;73:156-166. DOI: 10.1016/j.critrevonc.2009.02.001
14. Gotay C, Dunn J. Adherence to long-term adjuvant hormonal therapy for breast cancer. Expert Rev Pharmacoecon Outcomes Res 2011;11:709-715. DOI: 10.1586/erp.11.80
15. Kirk MC, Hudis CA. Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer. Clin Breast Cancer 2008;8:155-161. DOI: 10.3816/CBC.2008.n.016
16. Grunfeld EA, Hunter MS, Sikka P, Mittal S. Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Counsel 2005;59:97-102. DOI: 10.1016/j.pec.2004.10.005
17. Kahn KL, Adams JL, Epstein AM. Patient centered experiences in breast cancer. Predicting long-term adherence to tamoxifen use. Med Care 2007;45:17-21. DOI: 10.1097/01.mlr.0000257193.10760.7f
18. Fallowfield LJ. Treatment decision-making in breast cancer: the patient-doctor relationship. Breast Cancer Res Treament 2008;112:5-13. DOI: 10.1007/s10549-008-0077-3
19. Cluze C, Rey D, Huiart L, et al . Adjuvant endocrine therapy with tamoxifen in young womenwith breast cancer: determinants of interruptions vary over time. Ann Oncol 2012;23:882-890. DOI: 10.1093/annonc/mdr330
20. Bell RJ, Lijovic M, Fradkin P, et al. Lack of knowledge of hormone receptor status and use of endocrine therapy in invasive breast cancer. J Womens Health 2009;18:1975-1980. DOI: 10.1089/jwh.2008.1351
21. Elwyn G, Edwards A, Britten N. "Doing prescribing": how doctors can be more effective. Br Med J 2003;327:864-867. DOI: 10.1136/bmj.327.7419.864
22. Wengström Y, Aapro M, Leto di Priolo S, Cannon H, Georgiou V. Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study. Breast 2007;16:462-468. DOI: 10.1016/j.breast.2007.02.007
23. Albert U-S, Zemlin C, Hadji P, et al. The impact of breast care nurses on patients' satisfaction, understanding of the disease, and adherence to adjuvant endocrine therapy. Breast Care 2011;6:221-226. DOI: 10.1159/000329006
24. Raynor DK, Blenkinsopp A, Knapp P, et al. A systematic review of quantitative and qualitative research on the role and effectiveness of written information available to patients about individual medicines. Health Technol Assess 2007;11:1-6.
25. Trevena LJ, Davey HM, Barratt A, Butow P, Caldwell PA. Systematic review on communicating with patients about evidence. J Eval Clin Pract 2006;12:13-23. DOI: 10.1111/j.1365-2753.2005.00596.x
26. Van Gülick-Bailer M, Maurer K, Häfner H. Schedules for Clinical Assessment in Neuropsychiatry Deutsche Ausgabe (SCAN). Göttingen, 1995.
27. Lehrl S. Mehrfachwahl-Wortschatz-Intelligenztest: MWT-B. 5. Balingen: 5; 1999.
28. Fagerlin A, Zikmund-Fisher BJ, Ubel PA, Jankovic A, Derry HA, Smith DM. Measuring numeracy without a math test: development of the Subjective Numeracy Scale. Med Decis Making: Int J Soc Med Decis Making 2007;27:672-680. DOI: 10.1177/0272989X07304449
29. Mahler C, Jank S, Hermann K, et al. Psychometric properties of a German version of the "Satisfaction with Information about Medicines Scale" (SIMS-D). Val Health: J Int Soc Pharmacoeconomics Outcomes Res 2009;12:1176-1179. DOI: 10.1111/j.1524-4733.2009.00575.x
30. Decensi A, Gandini S, Guerrieri-Gonzaga A, et al. Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women. J Clin Oncol 1999;17:2633-2638.
31. Bruera E, Willey JS, Palmer LJ, Rosales M. Treatment decisions for breast carcinoma: patient preferences and physician perceptions. Cancer 2001;94:2076-2080. DOI: 10.1002/cncr.10393
32. Jenkins V, Fallowfield LJ, Saul J. Information needs of patients with cancer: results from a large study in UK cancer centres. Br J Cancer 2001;84:48-51. DOI: 10.1054/bjoc.2000.1573
33. Williams-Piehota P, Pizarro J, Schneider TR, Mowad L, Salovey P. Matching health messages to monitor-blunter coping styles to motivate screening mammography. Health Psychol: Off J Div Health Psychol, Amer Psychological Assoc 2005;24:58-67. DOI: 10.1037/0278-6133.24.1.58
34. Williams-Piehota P, Latimer AE, Katulak NA, et al. Tailoring messages to individual differences in monitoring-blunting styles to increase fruit and vegetable intake. J Nutr Educ Behav 2009;41:398-405. DOI: 10.1016/j.jneb.2008.06.006
35. Kessels RPC. Patients' memory for medical information. J R Soc Med 2003;96:219-222.
36. Ziller V, Kyvernitakis I, Knöll D, Storch A, Hars O, Hadji P. Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment - the COMPAS study. BMC Cancer 2013;13:407. DOI: 10.1186/1471-2407-13-407
37. Glombiewski JA, Nestoriuc Y, Rief W, Glaesmer H, Braehler E. Medication adherence in the general population. PLoS One 2012;7:e50537. DOI: 10.1371/journal.pone.0050537
38. Voils CI, Maciejewski ML, Hoyle RH, et al. Initial validation of a self-report measure of the extent of and reasons for medication nonadherence. Med Care 2012;50:1013-1019. DOI: 10.1097/MLR.0b013e318269e121